An observational study in Aortic Stenosis, Aortic Regurgitation and Mitral Stenosis, sponsored by Beijing Anzhen Hospital. Enrolling by invitation at 4 sites in China. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-13.
Sponsored by Beijing Anzhen Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 68 studies in Aortic Valve Stenosis with a site in China — 42 open to participants now, 50 under way, 3 of them phase 3. Aortic Valve Stenosis · China.
Among the 68 studies in Aortic Valve Stenosis with a site in China, this one has the largest planned enrollment of the 21 observational ones that give a count, is one of 11 that started in 2024, is one of 21 observational ones, reaches primary completion later than 33 of the 49 other live ones, and was the 68th registered.
1,026 studies on the registry are indexed under Aortic Valve Stenosis; 293 are open to participants now.
Browse Aortic Valve Stenosis studies →42 of the 68 studies in Aortic Valve Stenosis with a site in China are open now. Recruiting first, the newest first:
West China Hospital · Sites in China
Ages 35–80
Yan'an Affiliated Hospital of Kunming Medical University · Sites in China
Ages 18+
Beijing Balance Medical Technology Co., Ltd · Sites in China
Ages 60–100
Anhui Provincial Cancer Hospital · Sites in China
Ages 18–80 · Healthy volunteers
RenJi Hospital · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 209 Aortic Valve Stenosis studies recruiting now, 163 (78%) set no upper age limit and 9 (4%) stop at 75 or younger; 25 take children under 18; 14 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
68 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 11 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 12,000 is above the median of 200 across 435 observational studies indexed under Aortic Valve Stenosis.
Median enrollment 120 across the 47 interventional studies, 480 across the 21 observational. Of the 7 that completed or were terminated, 2 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 68 have an industry lead sponsor. The 10 most frequent:
Beijing Anzhen Hospital is the lead sponsor of 193 studies on the registry; 103 are open to participants now.
Beijing Anzhen Hospital has 4 studies filed under Aortic Valve Stenosis — fewer than ten, so there is no comparison to draw.
5 of the studies in Aortic Valve Stenosis with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07335900RenJi HospitalA Clinical Study Using FAPI-PET Imaging to Assess the Postoperative Effects of TAVI in Patients With Aortic Stenosis | 2026-12-30 |
| NCT07390513Chinese Academy of Medical Sciences, Fuwai HospitalElectrophysiological Outcomes After Transcatheter Aortic Valve Replacement | 2026-12-31 |
| NCT06891079Xijing HospitalVideodensitometric Angiographic Assessment of AR in the Cath-lab for Intraprocedural Guidance of TAVI in CHINA | 2026-12-31 |
| NCT07035847Chinese Academy of Medical Sciences, Fuwai HospitalTransaxillary TAVR With Solely Echocardiography Guidance | 2026-12-31 |
| NCT07414342Beijing Balance Medical Technology Co., LtdSafety and Efficacy of the RENATUS® Transcatheter Aortic Valve System for the Treatment of Severe Aortic Stenosis | 2027-09 |
Add all 5 to your calendar (.ics) → With an account.
Among the 68 studies in Aortic Valve Stenosis with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This community-based observational study primarily aims to estimate the prevalence, characterize the clinical spectrum, and identify associated risk factors for moderate or greater valvular heart disease (VHD) in China. Longitudinal follow-up will characterize VHD progression and assess long-term clinical outcomes among participants.
Valvular heart disease (VHD) represents a growing public health burden in China as the population ages. However, community-based evidence on its prevalence, clinical spectrum, associated factors, disease awareness, treatment, and long-term outcomes remains limited.
This study will characterize VHD subtypes, severity, and etiology, as well as cardiac structural and functional abnormalities, in community-based Chinese populations. Awareness, treatment, and valve intervention rates will also be assessed. Data collected during previous cohort visits will be used to examine associations between cumulative risk factor exposures and moderate-to-severe VHD, while prospective follow-up will characterize disease progression and long-term clinical outcomes. The diagnostic performance of synchronous electrocardiogram-phonocardiogram (ECG-PCG) signals will be evaluated using core laboratory echocardiographic findings as the reference standard.
Eligible adults from established community-based cohorts at selected sites in China are invited to participate during the current follow-up round. All participants will undergo standardized transthoracic echocardiography and synchronous ECG-PCG recording. An independent echocardiography core laboratory reviews image quality, confirms valvular diagnoses and severity grades, and assesses cardiac structure and function. Participants will undergo lifelong follow-up from the current study assessment to ascertain all-cause and cardiovascular mortality, heart failure, valve interventions, and other cardiovascular events. Repeat echocardiography and ECG-PCG recordings will be scheduled according to cohort follow-up arrangements.
The study population is drawn from established community-based cohorts within the China-PAR (Prediction for Atherosclerotic Cardiovascular Disease Risk in China) project at selected sites in China. Data are collected through current cohort follow-up assessments and review of existing cohort and medical records.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
- No additional disease-specific exclusion criteria.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will undergo standardized transthoracic echocardiography to assess valvular heart disease, as well as cardiac structure, function, and hemodynamics. Images and measurements will be acquired and stored according to a standardized protocol. A central echocardiography core laboratory will review image quality and confirm valvular disease diagnoses and severity.
Participants will undergo noninvasive, simultaneous electrocardiogram and phonocardiogram recording using a wearable device. Signals will be acquired, stored, and assessed for quality according to a standardized protocol. Exploratory analyses will evaluate the diagnostic value of these signals in identifying and characterizing valvular heart disease and other cardiac abnormalities, using core laboratory echocardiographic findings as the reference standard.
Moderate or greater valvular heart disease
Prevalence will be reported as the percentage of participants with at least moderate aortic stenosis, aortic regurgitation, mitral stenosis, mitral regurgitation, or tricuspid regurgitation. Diagnosis and severity grading will be confirmed by the echocardiography core laboratory. The presence or absence of moderate or greater valvular heart disease will be used as the outcome in risk factor analyses. Associations of demographic characteristics, cardiovascular risk factors, lifestyle and metabolic factors, and cumulative exposures with moderate-to-severe valvular heart disease will be examined using multivariable regression models.
Time frame: Baseline
Trivial or mild valvular heart disease
Percentage of trivial or mild valvular heart disease
Time frame: Baseline
Etiologic distribution of valvular heart disease
Percentage of participants with moderate or greater valvular heart disease in each etiologic category. Etiology will be classified using echocardiographic findings and available clinical information.
Time frame: Baseline
Awareness of valvular heart disease
Percentage of participants aware of their valvular heart disease before screening.
Time frame: Baseline
History of surgical or transcatheter valve intervention
Percentage of all participants with a history of surgical or transcatheter valve intervention before screening
Time frame: Baseline
All-cause mortality
Time frame: Up to 5 years
Cardiovascular mortality
Time frame: Up to 5 years
Valve intervention
Surgical or transcatheter valve intervention during follow-up
Time frame: Up to 5 years
Heart failure hospitalization
Unplanned hospitalization for new-onset or worsening heart failure during follow-up
Time frame: Up to 5 years
Plan to share: No
No publications or documents are linked to this record.
Started Jul 2024 (actual). Primary completion is estimated for Dec 2027, 41 months after the start.
Of 205 non-industry observational studies under Aortic Valve Stenosis, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 120. This study's planned 41 months is close to that.
Counting every sponsor, half of 242 studies reached it within 42 months; a quarter within 23 and three quarters within 86.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.